![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
;
Promising news for patients with #melanoma from the EA6194 phase 2 study led by ECOG-ACRIN @EAonc with support from @theNCI. Lead investigator Ahmad Tarhini @MoffittNews talks with @ecancer about #ASCO25 late-breaking data.
Neoadjuvant pembrolizumab + vidutolimod increases pathologic complete response rate in patients with resectable stage IIIB-D melanoma. Dr Ahmad Tarhini (@ATarhiniMDPhD) of @MoffittResearch talks about the ECOG-ACRIN EA6194 trial 👇 https://ecancer.org/en/video/12416-enhanced-pathologic-response-with-neoadjuvant-pembrolizumab-plus-vidutolimod-in-high-risk-resectable-melanoma #ASCO25
Thanks much @BladderCancerUS very much appreciate you all! @eaonc
Do you have advanced non-small cell #LungCancer and are aged 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: https://bit.ly/ea5221-achieve cc: @BalazsHalmosMD @efratdotan @CPresGeriOncMD
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
37
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
